Medical Condition News

RSS

Heart failure alters bone marrow to promote harmful inflammation

Heart failure (HF) alters the bone marrow (BM), reducing protective cells that regulate inflammation, reports a study conducted at Science Tokyo.

15 Oct 2026

A protective brain enzyme may counteract aging-associated cognitive decline

Cinzia Vicidomini, PhD, and Amar Sahay, PhD, of the Mass General Brigham Department of Psychiatry, the Harvard Stem Cell Institute and the Broad Institute of Harvard and MIT, are the lead and senior authors of a paper published in Nature Neuroscience, "An aging-sensitive secreted phospholipase confers neuroprotection and cognitive resilience."

15 Oct 2026

INmune Bio Inc. and Quantum Computing Inc. partner to apply quantum optimization and AI to advance Alzheimer’s drug research and explore new applications for XPro

INmune Bio Inc. and Quantum Computing Inc. today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other disease conditions.

From INmune Bio 15 Oct 2026

Experts call for lifelong care after brain and spinal injuries

In a new paper published in The Lancet Neurology, "Reframing traumatic brain injury and spinal cord injury as chronic multisystem disorders: toward integrated, long-term care," international experts across institutions and disciplines propose a fundamental shift in how traumatic brain and spinal cord injuries in adults are understood and managed. Sandro Marini, MD, of the Mass General Brigham Neuroscience Institute, is a co-first author, and Saef Izzy, MD, also of the Neuroscience Institute, is one of the co-senior authors, and the primary corresponding author.

14 Oct 2026

Study: First 90 days of antipsychotic treatment critical for metabolic changes

The first 90 days after starting antipsychotic treatment are crucial for changes in blood sugar and weight, finds a new study led by UCL researchers.

14 Oct 2026

New imaging technique detects subtle skin changes in scleroderma patients

Scleroderma (systemic sclerosis) is a rare, chronic, autoimmune disease that causes the body to produce too much collagen, leading to the hardening and thickening of the skin and internal organs.

14 Oct 2026

Precise brain circuit targeting may improve depression treatment outcomes

Stimulation of specific brain connections was associated with sustained improvement in people receiving deep brain stimulation (DBS) for treatment-resistant depression, Mount Sinai researchers reported.

14 Oct 2026

Epilepsy linked to higher risk of young-onset dementia

People with epilepsy may be more likely to develop young-onset dementia than people without epilepsy, according to a study published October 14, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

14 Oct 2026

Skin conductance measurements reveal link between insomnia and disrupted fear regulation

A new computational model using skin conductance measurements to estimate stress-related emotional arousal found a significant difference in learned fear and safety responses over time between adults with and without insomnia.

14 Oct 2026

Recurrent brain tumors undergo unique genetic changes after treatment

When patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when the cancer returns.

14 Oct 2026

Experimental gene therapy offers non-surgical option for hydrocephalus

Researchers at the University of Cincinnati College of Medicine have published the first proof-of-concept study showing the potential of an experimental gene therapy for hydrocephalus.

14 Oct 2026

WEHI study reveals a new immune pathway for fighting small cell lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally.

14 Oct 2026

Opioid use disorder diagnoses spike among commercially insured Americans

Commercially insured patients with diagnoses of opioid use disorder increased 32.7 percent nationally from 2022 to 2025, according to FAIR Health's Opioid Tracker.

14 Oct 2026

New study highlights severe depression risks for young doctor trainees

Every summer, more than 1,600 recent medical school graduates start training to become obstetrician-gynecologists at hospitals across the United States.

14 Oct 2026

Upcoming forum will share patient perspectives on non-cystic fibrosis bronchiectasis care

The Bronchiectasis and NTM Association today announced plans for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting for non-cystic fibrosis bronchiectasis (NCFB). This

14 Oct 2026

Biomechanical strain keeps heart valves strong for decades

Collagen plays a critical role in keeping heart valves strong, but the heart is surrounded by enzymes designed to break down collagen.

14 Oct 2026

CSHL researchers find way to make immunotherapy effective against colorectal cancer

Colorectal cancer has become the leading cause of cancer-related death for people under 50. Its most common forms generally aren't treatable, either through conventional means like chemotherapy or newer immunotherapy drugs.

14 Oct 2026

Investigational knee injection targets cartilage loss in osteoarthritis patients

Keck Medicine of USC has launched a clinical trial testing the safety and tolerability of a new investigational treatment and its potential effects on preventing cartilage deterioration in people with knee osteoarthritis, the most common form of the disease.

14 Oct 2026

Chronic inflammation spikes during the earliest phase of cardiovascular-kidney-metabolic syndrome

In a nationally representative sample of more than 4,000 American adults, a common marker of inflammation was nearly doubled in people in the first stage of the syndrome, defined by excess or unhealthy body fat, compared with those with no metabolic risk factors.

14 Oct 2026

Seragy launches with €12 million financing to advance quantitative biomarkers for neurodegenerative diseases

seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony.

14 Oct 2026